Duyuru • May 14
Converium Capital Sends Letter to CVS Group On May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime. Duyuru • Apr 23
Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026 CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion. Duyuru • Mar 25
CVS Group plc Announces Board and Committee Changes CVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026. Duyuru • Oct 24
CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares. CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026. Duyuru • May 20
Anima Care UK Limited acquired Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million. Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services.
For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million.
The expected completion date of the transaction is within the next five weeks.
Anima Care UK Limited completed the acquisition of Crematoria operations of CVS Group plc (AIM:CVSG) on May 19, 2025. In related transaction, CVS Group plc completed the acquisition of VPP Group. Christopher Golden, James Steel and Andrew Clark of Peel Hunt LLP acted as financial advisor for CVS Group plc. Toby Flaux, Michael Burke, James Thompson and Milo Bonser brokered the transaction. Duyuru • Apr 25
Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million. Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services.
For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million.
The expected completion date of the transaction is within the next five weeks. Duyuru • Nov 20
CVS Group plc Proposes Final Dividend, Payable on 29 November 2024 Subject to shareholder approval at the AGM, CVS Group plc intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024. Duyuru • Jun 19
CVS Group plc Announces Resignation of Ben Jacklin as Executive Director CVS Group plc announces that Ben Jacklin, Executive Director, has resigned. Ben's managerial and operational responsibilities, including the provision of clinical guidance to the Board, have been assumed by other senior members of the Group. Duyuru • May 01
CVS Group plc Announces Board Changes CVS Group plc announced the appointment of David Wilton as Chair with effect from 1 May 2024. David has served as an Independent Non-executive Director of the Company since September 2021. David is a qualified Chartered Accountant with more than 30 years' post-qualification experience as a Chief Financial Officer, Non-Executive Director (NED), Chair and consultant after many years in corporate finance, primarily in mid-cap M&A with Rothschilds. David has held roles in both public and private-equity backed companies including as CFO of Sumo Group plc, Group Finance Director of WYG plc and NED and Chair of the Audit Committee of Sweett Group plc. David was NED and subsequently Chair at Frontier Developments plc until November 2023. David is currently also NED and Chair Designate at Gateley (Holdings) plc. He has extensive experience of people businesses and of regulatory processes. David also brings to the Chair role a significant amount of technical expertise, which will support CVS in its strategic delivery of investment in technology. David Wilton's appointment follows a comprehensive search by the Nomination Committee, supported by a blue chip recruitment firm who sourced a number of high quality candidates. The Board would like to thank Deborah Kemp, the Group's Senior Independent Director who has been acting as Interim Chair during the search period. David will remain as Audit Committee Chair until this process is completed, at which point he will then step down as a member of the Audit Committee. Duyuru • Oct 27
CVS Announce Director Changes CVS announced that its Chair Richard Connell has taken the difficult decision to resign with immediate effect due to ill health. Deborah Kemp, the Group's Senior Independent Director will assume the role of Chair for the interim period whilst the Board commences a process to appoint a permanent successor. Duyuru • Sep 21
CVS Group plc Recommends Final Dividend, Payable on 8 December 2023 CVS Group plc recommends continuation of progressive dividend policy, with the payment of a final dividend of 7.5 pence per Ordinary share (2022: 7.0 pence). The ex-dividend date is 2 November 2023 and the dividend payment date is 8 December 2023.